Browse the evidence

Lower adipose NPR-C mRNA expression and higher NPR-A mRNA expression after weight loss predict better long-term weight maintenance and improved insulin sensitivity, independent of the weight maintenance intervention.

Your body's molecular response to weight loss (specifically the ANP system in fat tissue) may predict how well you maintain your weight and insulin sensitivity long-term. While you cannot change this directly, it suggests that personalized monitoring might be needed for those with less favorable molecular profiles.

Setmelanotide, an MC4R agonist, significantly reduces hunger and improves health-related quality of life in patients with POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you or your child has a confirmed diagnosis of POMC, LEPR, or BBS-related obesity, standard diet and exercise plans are unlikely to resolve the insatiable hunger (hyperphagia) because they don't fix the underlying genetic signaling error. Setmelanotide is an approved targeted therapy that directly addresses this mechanism, significantly reducing hunger scores and improving quality of life in clinical trials. Consult a specialist in rare metabolic disorders to determine eligibility.

Leptin replacement therapy is effective for reducing hunger and weight in patients with congenital leptin deficiency (homozygous LEP variants) but is ineffective in patients with defects downstream of the leptin receptor (e.g., POMC, PC1/3, MC4R deficiencies).

Leptin injections are highly effective for the rare condition of congenital leptin deficiency, significantly reducing hunger and weight. However, they are useless for patients with other genetic causes of obesity (like POMC or MC4R defects) because the body's ability to respond to leptin is broken downstream. Genetic testing is essential before considering this therapy.

Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).

Current GLP-1 drugs cause nausea by activating the Area Postrema in the brain, but weight loss is achieved by activating other brainstem areas (NTS). This separation suggests future drugs could be designed to minimize nausea while maintaining weight loss benefits.

Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.

Bariatric surgery and GLP-1 medications both work by activating specific brain pathways that reduce hunger and food intake. This shared mechanism explains why both are effective for severe obesity, even though one is surgical and the other is pharmacological.

Inhibiting Gs signaling specifically in K cells reduces plasma GIP levels and worsens glucose tolerance after refeeding.

This finding highlights that the natural Gs-mediated signaling in gut K cells is essential for maintaining normal blood sugar levels after eating. Disrupting this specific pathway impairs the body's ability to manage glucose spikes.

Elevated plasma levels of COL6A3-derived endotrophin, driven by increased body mass index (BMI), causally mediate an increased risk of coronary artery disease (CAD).

This research highlights that high body fat increases a specific protein fragment called endotrophin, which directly contributes to heart disease risk. The good news is that reducing body fat lowers these levels, suggesting that weight management strategies are effective not just for general health, but specifically for mitigating this biological pathway to heart disease.

Diet-induced changes in endogenous gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) do not reliably predict or control ad libitum energy intake in humans.

Do not rely on macronutrient manipulation (like Keto or Low-Fat) to regulate your appetite through hormones. This study proves that even when hormones change significantly, they do not predict how much you will eat. Instead, focus on food properties: lower energy density and fewer hyper-palatable combinations (fat/sugar/sodium) are more effective for controlling intake than hormone-targeting diets.

Endogenous gut hormone concentrations achieved through dietary changes are orders of magnitude lower than pharmacological doses, explaining why diet fails to suppress appetite while drugs succeed.

You cannot replicate the effects of GLP-1 drugs (like Ozempic) through diet alone because the hormonal concentrations achieved by eating are too low. Diet changes affect hormones, but not enough to significantly reduce appetite or energy intake.

Genetic loss-of-function variants of the GIP receptor are associated with lower body mass index (BMI) and reduced obesity prevalence in humans.

People with certain genetic variations that reduce GIP receptor function tend to have lower body weight. This genetic insight supports the development of drugs that block GIP receptors to achieve similar weight loss benefits.

Semaglutide increases the risk of non-serious gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, in patients at increased risk of cardiovascular events.

Expect stomach issues like nausea, vomiting, or diarrhea when starting semaglutide. These are common, usually get better over time, and are not considered 'serious' adverse events. Managing diet and starting with a low dose can help mitigate these effects.

High-dose tirzepatide (15mg/week) is associated with a significantly increased risk of overall gynecologic tumors compared to controls, with an odds ratio of 2.37.

If you are taking high-dose tirzepatide (15mg/week), be aware that this network meta-analysis found a statistically significant increase in gynecologic tumor risk compared to controls. The absolute risk increase is small (0.57%), but it exists. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Both high-dose (15mg/week) and low-dose (5mg/week) tirzepatide are associated with a significantly elevated risk of intra-uterus tumors.

If you are taking tirzepatide (whether 5mg or 15mg weekly), be aware that this network meta-analysis found a statistically significant increase in the risk of intra-uterus tumors. The risk appears to be present at both low and high doses. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Tirzepatide reduces the incidence of heart failure hospitalizations, need for treatment intensification, and mortality due to cardiovascular causes in patients with heart failure and reduced ejection fraction.

If you have heart failure and reduced ejection fraction, Tirzepatide can reduce your risk of hospitalization and cardiovascular mortality.

Obeticholic acid reduces liver fibrosis but does not resolve NASH, and is associated with significant side effects like pruritus and increased LDL.

Obeticholic acid can reduce liver scarring (fibrosis) but does not cure the underlying inflammation (NASH). It causes itching in over 50% of patients at higher doses and raises LDL cholesterol, which may need to be managed with statins. It is not a first-line cure.

Initiation of GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes on stable levothyroxine therapy significantly increases the risk of new-onset atrial fibrillation or flutter (AF/Aflutter) compared to SGLT2 inhibitors.

If you take levothyroxine and start a GLP-1RA (like Ozempic or Wegovy), your thyroid hormone levels may become too high because you lose weight or absorb the medication differently. This increases your risk of irregular heartbeats (AF). You need closer monitoring of your TSH levels and likely a reduction in your levothyroxine dose shortly after starting the GLP-1RA to prevent this.

GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide) reduce hepatic lipid accumulation in MASLD patients, primarily through indirect mechanisms involving weight loss and reduced fatty acid deposition, and directly by improving insulin sensitivity and suppressing de novo lipogenesis.

GLP-1 agonists like semaglutide and tirzepatide are effective treatments for reducing liver fat in people with MASLD, especially if they also have type 2 diabetes or obesity. They work by improving insulin sensitivity and directly reducing fat production in the liver, in addition to helping with weight loss. While they significantly reduce liver fat, they may not reverse advanced scarring (fibrosis). Consistency is key, as side effects and cost can lead to stopping treatment.

GLP-1 receptor agonists have limited efficacy in reversing advanced hepatic fibrosis compared to their ability to reduce hepatic steatosis.

If you have advanced liver scarring (fibrosis), GLP-1 medications may not reverse it, even though they will likely reduce liver fat. Newer multi-agonists (like resmetirom or dual agonists) might be needed for fibrosis.

Retatrutide increases the incidence of adverse events, particularly nausea, vomiting, and decreased appetite, in a dose-dependent manner compared to placebo.

While effective, retatrutide causes more side effects than placebo, including nausea, vomiting, and constipation. These side effects increase with higher doses (8mg and 12mg). Patients should be prepared for these potential issues, which may affect adherence.

Genetic factors significantly predispose individuals to obesity, with heritability estimates exceeding 70% for fat difference, involving genes like LEP, LEPR, and MC4R.

If you have a family history of obesity, be aware that your body may fight weight loss more strongly. Focus on consistent, sustainable habits rather than quick fixes, and consider seeking professional guidance to navigate biological challenges.

Administration of the plasma protein encoded by the obese gene (leptin) reduces body weight in genetically obese (ob/ob) mice by restoring energy balance.

This foundational research identifies leptin as a key hormone regulating body weight. For individuals with specific genetic leptin deficiencies, leptin therapy can be effective. For the general population, this highlights the importance of hormonal balance in weight management, though direct leptin supplementation is not a standard or effective treatment for common obesity due to leptin resistance.

Obesity induces chronic low-grade inflammation in adipose tissue, which impairs insulin signaling and leads to insulin resistance.

Excess body fat, especially around the midsection (visceral fat), is not just inert storage; it actively releases inflammatory chemicals that block your body's ability to use insulin. This biological change is a primary driver of metabolic disease, meaning that managing inflammation and fat distribution is as critical as calorie counting for metabolic health.

Macrophage infiltration into adipose tissue is a primary mechanism by which obesity causes insulin resistance.

Reducing the accumulation of immune cells (macrophages) in fat tissue may improve insulin sensitivity. This suggests that anti-inflammatory strategies could be beneficial for metabolic health in obesity.

Senescent cells secrete a complex, heterogeneous proteome (SASP) that includes specific proteins (GDF15, STC1, SERPINs) which correlate with human aging and serve as potential plasma biomarkers for cellular senescence burden.

This research identifies specific proteins (GDF15, STC1, SERPINs) secreted by senescent cells that correlate with aging in human blood. While not yet a commercial test, these markers offer a potential way to measure 'senescent burden' in the future, linking cellular aging to systemic health.